Camp4 Therapeutics CAMP 深 沪

美股大行评级 | 富国上调闪迪目标价从1400美元升至1550美元；塔吉特、Workday、应用材料等获多家大行上调目标价

今日重点评级关注：富瑞：维持ProMIS Neurosciences"买入"评级，目标价从69美元升至100美元；Benchmark：维持Cineverse"买入"评级，目标价从12美元升至14美元

今天 13:37

Piper Sandler Reiterates Overweight on Camp4 Therapeutics, Raises Price Target to $15

Piper Sandler analyst Edward Tenthoff reiterates Camp4 Therapeutics (NASDAQ:CAMP) with a Overweight and raises the price target from $12 to $15.

08-15 00:22

Camp4 Therapeutics Q2 EPS $(0.58) Misses $(0.21) Estimate, Sales $1.779M Miss $1.897M Estimate

Camp4 Therapeutics (NASDAQ:CAMP) reported quarterly losses of $(0.58) per share which missed the analyst consensus estimate of $(0.21) by 176.19 percent. This is a 6.45 percent increase over losses of $(0.62) per share from the same period last year. The company reported quarterly sales of $1.779 mi...

08-14 04:34

CAMP4 Therapeutics Secures $50 Million Private Financing

CAMP4 Therapeutics Corporation ( ($CAMP) ) has issued an update. On August 3, 2...

08-04 19:29

CAMP4 Therapeutics Announces Second Closing of $100 Million Private Placement

08-04 11:00

CAMP4 Therapeutics Receives Clearance From Australia’s TGA And Local HREC To Initiate Phase 1/2 Clinical Trial Of CMP-002, Disease-Modifying Therapeutic For SYNGAP1-Related Disorder

Planned first-in-human clinical trial to assess a disease modifying intervention for patients with SYNGAP1-related disorder Regulatory milestone enables Company to raise up to $50 million through second closing of private placement announced September 2025 CAMBRIDGE, Mass., July 27, 2026 (GLOBE NEWS...

07-27 19:05

CAMP4 Therapeutics Secures Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of CMP-002 in Patients With SYNGAP1-Related Disorder

CAMP4 Therapeutics received clearance from Australia's TGA and HREC to initiate a Phase 1/2 clinical trial for CMP-002, a potential disease-modifying therapy for SYNGAP1-related disorder. This approval marks a significant step toward the first-in-human study for this condition, which currently has no approved treatments. The clearance also enables the company to raise up to $50 million through a second closing of its private placement, with notab...

07-27 11:00

CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CAMP4 Therapeutics Corporation granted a non-qualified stock option to a newly hired employee, allowing the purchase of 8,000 shares at $4.21 per share. The option vests over four years, with 25% of shares vesting after the first year and the rest vesting monthly. The grant aligns with Nasdaq Listing Rule 5635(c)(4) and is part of the Company's 2026 Inducement Plan. CAMP4 focuses on developing RNA-targeting therapeutics to treat genetic diseases ...

07-17 20:05

Positive Report for CAMP4 Therapeutics Corporation (CAMP) from J.P. Morgan

J.P. Morgan analyst Anupam Rama upgraded CAMP4 Therapeutics Corporation to a Bu...

06-23 20:37

CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMP4 Therapeutics granted non-qualified stock options to three new employees on June 15, 2026, under Nasdaq Rule 5635(c)(4). The options, totaling 39,000 shares with an exercise price of $3.96, vest over four years. CAMP4 focuses on developing RNA-targeting therapeutics to treat genetic diseases by amplifying healthy protein levels.

06-19 20:05